Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02614937

Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion

Open Label Squalamine Lactate Ophthalmic Solution for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

Sponsor: Cumberland Valley Retina Consultants, PC

Conditions Macular Edema Retinal Vein Occlusion

Interventions Squalamine Lactate Ophthalmic Solution, 0.2% ranibizumab

Updated 6 times since 2017 Last updated: Nov 24, 2015 Started: Apr 30, 2013 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02614937, this PHASE1/PHASE2 trial focuses on Macular Edema and Retinal Vein Occlusion and remains completed. Sponsored by Cumberland Valley Retina Consultants, PC, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cumberland Valley Retina Consultants, PC
Ohr Pharmaceutical Inc.

Data source: Ohr Pharmaceutical Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.